Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia-Reference-Cited by-同舟云学术

Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia

Published:2020-10-28 Issue:6 Volume:3 Page:1042-1062
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Hatzipantelis Cassandra J.¹,Langiu Monica¹,Vandekolk Teresa H.¹,Pierce Tracie L.¹,Nithianantharajah Jess²,Stewart Gregory D.¹,Langmead Christopher J.¹^ORCID

Affiliation:

1. Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia

2. Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria 3052, Australia

Publisher

American Chemical Society (ACS)

Subject

Pharmacology (medical),Pharmacology

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.0c00117

Reference320 articles.

1. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016

2. Premature Mortality Among Adults With Schizophrenia in the United States

3. Childhood Attentional Dysfunctions Predict Social Deficits in Unaffected Adults at Risk for Schizophrenia

4. A Prospective Study of Childhood Neurocognitive Functioning in Schizophrenic Patients and Their Siblings

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring orphan GPCRs in neurodegenerative diseases;Frontiers in Pharmacology;2024-06-04

2. Identification and Characterization of ML321: A Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity;ACS PHARMACOL TRANSL;2023

3. Identification and Characterization of ML321: A Novel and Highly Selective D₂ Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity;ACS Pharmacology & Translational Science;2022-12-30

4. Identification and Characterization of ML321: a Novel and Highly Selective D2Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity;2022-11-16

5. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia;CNS Drugs;2022-07-13